Forgot Password

Life Sciences Queensland Limited and Springfield City Group in collaboration to partner health services and manufacturing in Queensland.

VIPs converge at the Life Sciences Queensland and Springfield City Group second Future of Health Series to push biotechnology and manufacturing capability in Australia.

Almost 100 dynamic stakeholders with a passion and ambition to build biotechnology and manufacturing capability met last week to address how biomanufacturing can grow across the sector.

In the second Future of Health Series, Life Sciences Queensland and Springfield City Group partnered together to create a collaborative environment where experts were able to meet face-to-face to discuss biotechnology, medical technology, and manufacturing in Springfield.  Presentations sparked conversations and a continuing theme that emerged for scientists, entrepreneurs, and community stakeholders was how new opportunities, partnerships and decisions will shape the sector for years to come.

The Honourable Milton Dick, MP, Member for Oxley (pictured with Clare Blain), gave the keynote address. In his presentation he stated that the future of medical technology and advancement sits with the smartest minds and partnerships with locations like Greater Springfield providing a place where innovative health technologies and manufacturing can grow. “There is extraordinary value in medical technology for the future of health,” he stated. “Medtech is saving lives, but it is also a key economic driver for our country.”

Life Sciences Queensland, CEO, Clare Blain, concurs and added organisationally they understand the key role innovation plays in the life sciences. “LSQ is the amplifier of the Queensland life sciences ecosystem,” stated Clare, “Our focus is to bring the best and brightest minds together to collaborate and rise to world challenges.”

Mark Kendall, Founder and CEO of WearOptimo, and Australian grown Medtech company, provided an opportunity to address how Australia’s biotechnology industry is transforming health. He noted that a key element to a robust biotechnology industry is one where research and development or the ‘idea phase’ can lead to production without leaving the country. “Ideally,” Mark said, “Australia should have the capability to do both.”

Dr Kym Baker, General Manager of Patheon by Thermo Fisher Scientific stated that advancements have already been made to manufacture modern miracles that lead to improvements in immunotherapies, vaccines, and personalised treatments. “We have great potential in Queensland,” Dr Baker noted. “Don’t underestimate our capability.”

Another aspect of increasing capability that has the potential to have far reaching positive benefit within health is artificial intelligence. Dr Stephanie Chauosis, Partnerships Manager with Datarwe, presented how accessing and leveraging real world data is possible. “We interact with AI every day and have this technology integrated into our lives now,” she stated,  “it can be rapidly translated to reduce burden on Queensland’s health system and improve health outcomes.”

Emeritus Fellow at QIMR Berghofer Medical Research Institute and Springfield City Group Advisor, Professor Frank Gannon, provided a broad picture of experiences in biotechnology and manufacturing from all over the world. “What can we learn from these international experiences and then apply to our own biotech ecosystems?” he posed to the audience.  Among the common international themes identified, Professor Gannon highlighted that, “success comes from foresight,” and that an appropriate environment, specialised talent, and communication must be right if biomanufacturing is to gain a foothold.

The Springfield Group believes BioPark Australia is this type of environment.  Nestled within the fast-emerging city of Greater Springfield, the BioPark is well-placed as a location for biotechnology and manufacturing to thrive.

Future of Health Series 2022 event photos available here.

For further media information contact:

Clare Blain
info@lsq.com.au
07 3331 3955

Nadine Pobar
n.pobar@springfieldcity.com
0419 759 503

About:
Life Sciences Queensland is focussed on facilitating the future growth and sustainability of Australia’s life sciences industry. The organisation highlights the key role that life sciences innovation plays to feed, fuel and heal our citizens.

Springfield City Group:  Greater Springfield, located right on Brisbane’s doorstep, is Australia’s fastest emerging new city. It drives one of the nation’s fastest growing urban growth corridors, and other than Canberra, it is the only fully master planned city to be built in Australia.

The interconnected pillars of health, education and information technology continue to be at the core of this plan, with precincts and economic drivers established to eventually cater for all forms of health, wellness and education to meet the city’s job target of 52,0000 by 2030.

Springfield City Group (formerly Springfield Land Corporation) is the master developer of Greater Springfield and has been instrumental to the emerging city ‘s continuing success.

L-R: Raynuha Sinnathamby – Springfield City Group, Dr Stephanie Chaousis – Datarwe, Maha Sinnathamby AM – Springfield City Group, Dr Christine Williams – Life Sciences Queensland Limited, Mr Milton Dick MP Member for Oxley, Prof. Rob Stable AM – Springfield City Group and Prof. Frank Gannon – Springfield City Group